Oxeltis

Many programs start with strong biology but struggle to convert early hits, fragments, or tool compounds into viable leads due to limited medicinal chemistry resources.

We address this by:

• Seamless integration of the drug discovery value chain.

  in silico design (CADD, SBDD, LBDD, AI/ML) with high-quality synthesis and Assay development/in vitro biological screening in partnership with Pure player and experts in their field.

• Rapid hit-to-lead and lead optimization, with a track record of delivering high-quality compounds efficiently and a highly skill team of chemists (50% Ph.D., 50% M.Sc.)

• Expertise in complex and enabling chemistries, supported by our hybrid SFC platform for rapid purification and scale-up (up to 25g/day) of chiral/achiral mixtures.

• Comprehensive biological services, including assay design, in vitro screening, and early pharmacology profiling, integrated with chemistry to accelerate DMTA cycles and decision-making.